Bipolar Disorder Therapeutics Market Report 2026

The bipolar disorder therapeutics market size has grown strongly in recent years. It will grow from $7.82 billion in 2025 to $8.28 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to increasing diagnosis of bipolar disorder, growing awareness of mental health conditions, expansion of psychiatric care services, availability of established pharmacological treatments, rising healthcare expenditure.

The bipolar disorder therapeutics market size is expected to see strong growth in the next few years. It will grow to $10.39 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing demand for precision psychiatry solutions, expansion of long-acting injectable therapies, growing integration of digital therapeutics, rising focus on treatment adherence improvement, increasing investment in mental health research. Major trends in the forecast period include increasing development of novel mood stabilizing therapies, rising adoption of atypical antipsychotic medications, growing focus on personalized mental health treatment, expansion of combination drug therapies, enhanced integration of digital mental health support.

The rising healthcare expenditure is expected to drive the growth of the bipolar disorder therapeutics market in the coming years. Healthcare infrastructure encompasses all costs associated with medical care, preventive measures, public health programs, rehabilitation, community health initiatives, and health research. The increase in healthcare spending can be attributed to several factors, including an aging population, a higher prevalence of chronic diseases, and rising drug costs, all of which substantially contribute to the growing need for medical services and treatments. As awareness of mental health conditions increases, the diagnosis of bipolar disorder rises, resulting in a greater demand for therapeutic interventions. For example, in November 2023, the Canadian Institute for Health Information, a Canada-based non-profit organization, reported that total health spending in Canada is expected to grow by 2.8% in 2023, following a modest increase of 1.5% in 2022. Consequently, the rising healthcare expenditure is fueling the growth of the bipolar disorder therapeutics market.

Major companies operating in the Bipolar Disorder Therapeutics market are focusing on developing new treatments for depressive episodes associated with bipolar I or II disorder to reach larger patient populations, boost sales, and increase revenue. Among bipolar disorders, bipolar depression is the most common and severe clinical manifestation. Compared to manic or hypomanic episodes, these depressive episodes are associated with a poorer prognosis, longer duration, and higher recurrence rates. For example, in March 2024, the EDIT-B consortium, a France-based collaborative organization specializing in innovative diagnostic tools and biomarkers, introduced myEDIT-B, a novel blood diagnostic tool designed to provide objective biological data to help psychiatrists and healthcare professionals make accurate diagnoses. It examines RNA editing-based biomarkers and has shown sensitivity and specificity rates above 80%. By enabling faster and more precise diagnoses, potentially reducing the wait time to within four weeks, myEDIT-B aims to address the significant issue of misdiagnosis in mental health, as approximately 40% of individuals diagnosed with depression may actually have bipolar disorder.

In June 2023, Brain Therapeutics, a Greece-based central nervous system specialty company, acquired the prescription drug brand Lazap (olanzapine) from the Greek pharmaceutical company Lyofin Ltd for an undisclosed amount. This acquisition allows Neuraxpharm Group to expand its therapeutic product portfolio in Greece and Europe. The agreement is intended to broaden Neuraxpharm's presence in Greece and leverage its extensive expertise in the central nervous system (CNS) to provide the appropriate products from its broad lineup to CNS patients, healthcare professionals, pharmacists, and hospitals across the country, effectively addressing the healthcare needs of patients in Greece. Lyofin Ltd. is a Greece-based pharmaceutical company.

Major companies operating in the bipolar disorder therapeutics market are AbbVie Inc., Pfizer Inc., Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb, GlaxoSmithKline PLC, Janssen Pharmaceuticals, Novartis AG, Otsuka Pharmaceutical Co. Ltd., Eli Lilly and Company, Gedeon Richter PLC, Sumitomo Pharma Co. Ltd., H. Lundbeck A/S, Sanofi S.A., Allergan plc, Takeda Pharmaceutical Company Limited, Sunovion Pharmaceuticals Inc., Alkermes plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., Johnson & Johnson, NeuroRx Inc., IntraCellular Therapies Inc., Vanda Pharmaceuticals Inc., Sage Therapeutics Inc.

North America was the largest region in the bipolar disorder therapeutics market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the bipolar disorder therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bipolar disorder therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the bipolar disorder therapeutics market by increasing costs of imported active pharmaceutical ingredients, excipients, packaging materials, and manufacturing equipment used in psychiatric drug production. Pharmaceutical manufacturers in North America and Europe are most affected due to globalized API supply chains, while Asia-Pacific faces pricing pressure on generic drug exports. These tariffs are increasing drug production costs and influencing pricing strategies. However, they are also encouraging local API manufacturing, regional pharmaceutical production, and increased investment in domestic drug development capabilities.

The bipolar disorder therapeutics market research report is one of a series of new reports that provides bipolar disorder therapeutics market statistics, including bipolar disorder therapeutics industry global market size, regional shares, competitors with a bipolar disorder therapeutics market share, detailed bipolar disorder therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the bipolar disorder therapeutics industry. This bipolar disorder therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Bipolar disorder therapeutics involve medications, including mood stabilizers, antidepressants, antipsychotics, and psychological counseling, aimed at managing symptoms. These therapeutics are used in the treatment and management of bipolar disorders.

The primary types of drugs in bipolar disorder therapeutics include mood stabilizers, antipsychotic drugs, antidepressant drugs, and other medications. Mood stabilizers are a class of drugs used to manage and treat bipolar disorders. Their mechanisms include selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors, benzodiazepines, beta-blockers, and others. These medications are made available through hospital pharmacies, retail pharmacies, and online pharmacies.

The bipolar disorder therapeutics market includes revenues earned by entities by family-focused therapy, interpersonal and social rhythm therapy, cognitive behavioral therapy and dialectical behavior therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.